The University of Texas MD Anderson Cancer Center is holding a symposium for patients with lymphoma and myeloma, and for their caregivers and family members, providing all with access to the latest research updates and leading experts in the field.
The Feb. 6 event, “Lymphoma/Myeloma Update for Patients: What’s New for 2016?,” will be at the San Antonio Marriott Northwest, 3233 NW Loop 410, San Antonio, Texas, and is sponsored by the Leukemia & Lymphoma Society, Patient Power, and Multiple Myeloma Opportunities for Research and Education (MORE).
“This is a tremendous opportunity for patients and their caregivers and families to hear from some of the top experts in all areas of treatment for lymphoma and myeloma,” Jatin Shah, MD, associate professor at MD Anderson, said in a press release. “This event is designed to answer patients’ questions about the newest research and therapies for these diseases.”
Lymphoma is a cancer that attacks the lymphatic system, specifically white blood cells, and myeloma starts in the bone marrow in plasma cells. During the conference, presenters and speakers will discuss state-of-the-art advances and therapies, such as coping techniques for chronic diseases, upcoming clinical trials for multiple myeloma, stem-cell transplantation or CAR T-cells, and other immunotherapies. Additionally, the symposium will provide general information about lymphoma and myeloma, and inform patients about new treatment options for recently diagnosed and relapsed lymphoma or myeloma and regarding transplant therapy. More information on the presentations can found on the symposium agenda.
Anyone wishing to attend the conference can register online or by calling 713-745-6130. The event starts with registration, followed by a myeloma session from 8 a.m. to 12.30 p.m., and a lymphoma session from 1 p.m. to 5.30 p.m. local time.
Hodgkin lymphoma (HL) survivors are at a greater risk of developing coronary heart disease, most likely due to their exposure to radiation of the heart during cancer treatment, researchers said in a study published in Oncology Times. Findings of a linear relationship between radiation dose and heart disease have been described for other cancer forms, but this is the first evidence that the relationship also appears to hold true in HL.
